BioNxt Solutions Prepares for Human Bioequivalence Study For MS
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata to Participate in Multiple Upcoming Investor Conferences15.5.2025 16:15:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / INNODATA INC. (Nasdaq:INOD), a leading data engineering company, today announced that it will participate in several upcoming investor conferences in May and June 2025. The scheduled conferences include: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025, Minneapolis TD Cowen 53rd Annual Technology, Media & Telecom Conference May 29, 2025, New York Stifel's Eighth Annual Boston Cross Sector Insight Conference June 4, 2025, Boston Maxim Group 2025 Virtual Tech Conference June 5, 2025, Virtual Mizuho Technology Conference 2025 June 10, 2025, New York Jack Abuhoff, CEO, and Aneesh Pendharkar, SVP of Finance and Corporate Development, will be available for one-on-one meetings with investors at each conference. Investors who wish to request a meeting with Innodata at any of these conferences should contact their representative at the sponsoring investment firm. Additionally, Jack Abuhoff will be presenting at the TD Cowen
Loar Announces Pricing of Secondary Public Offering14.5.2025 21:55:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 14, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the pricing of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders at $83.41 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 16, 2025, subject to customary closing conditions. The selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the offering. Moelis & Company, Citigroup and RBC Capital Markets are additionally acting as book runners. Blackstone is acting as co-manager. An automatic shelf regis
Maxon Introduces New Real-Time Rendering and Cinematic Previews Solution for Architects14.5.2025 02:10:00 CEST | Press release
Maxon gives first preview of new solution with partner Vectorworks at AIA Conference on Architecture & Design 2025 BAD HOMBURG, GERMANY / ACCESS Newswire / May 14, 2025 / Maxon, maker of powerful, approachable software solutions for creators working in 2D and 3D design, motion graphics, visual effects, gaming and more, is further optimizing its cinematic rendering technology for architectural visualization (ArchViz). For decades, Maxon's technology has empowered top artists to achieve the impossible in both the real world and imaginary-from architecture, construction and product design, to mind-bending visual effects, animation and 3D sculpting. Now, that same level of excellence is being engineered specifically for architects and designers-expanding on the power of Maxon's Cinema 4D and Redshift solutions to meet the demands of real-world, real-time architecture design workflows. Seamlessly integrating with major CAD and BIM tools like Vectorworks, this new platform will allow users t
Loar Announces Launch of Secondary Public Offering13.5.2025 16:26:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the launch of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Such selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the proposed offering. Blackstone is acting as co-manager. An automatic shelf registration statement (including a base prospectus) relating to this offering of common stock was filed by Loar with the Securities and Exchange Commission (the "SEC") on May 1, 2025 and became effec
Detego Global Announces Sponsorship of British Police Rugby Team for 2025 Centenary Tour of South Africa13.5.2025 12:30:00 CEST | Press release
HORSHAM, UNITED KINGDOM / ACCESS Newswire / May 13, 2025 / Following the resounding success of their sponsorship of the England Police Rugby Team's 2024 South African tour, Detego Global, the leading provider of cutting-edge digital forensics and investigative technology, is proud to announce its sponsorship of the British Police Rugby Team's 2025 centenary tour of South Africa, bringing together players from all four nations of England, Ireland, Scotland, and Wales. This new partnership strengthens a shared commitment to community engagement and global cooperation whilst marking an important occasion - the beginning of the British Police Rugby Team's centenary celebrations. Founded in 1925, the British Police Rugby Team has upheld a proud tradition of sporting excellence and service for a century. The 2025 tour of South Africa launches a year of commemorative events and fixtures, starting with two major matches, including one at the world-famous Hollywoodbets Kings Park Stadium in Dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom